{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:08Z","timestamp":1784557028539,"version":"3.55.0"},"reference-count":13,"publisher":"Bioscientifica","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We present the case of a 60-year-old female who developed repeated atraumatic stress fractures. She was initially diagnosed with osteoporosis based on her dual-energy X-ray absorptiometry (DXA) scan bone mineral density (BMD) T-scores and started on denosumab therapy. Secondary osteoporosis screen revealed abnormal myeloma screen and low serum phosphate levels. It was thought that the patient had multiple myeloma with associated Fanconi-related tubular dysfunction. However, fibroblast growth factor-23 (FGF-23) levels were grossly elevated, making Fanconi syndrome unlikely. The patient was subsequently diagnosed with two separate conditions, namely cardiac amyloid light-chain (AL) amyloidosis and FGF-23-related hypophosphataemia, likely due to tumour-induced osteomalacia. This case highlights the importance of excluding osteomalacia as a cause of low BMD and checking FGF-23 levels in the workup for hypophosphataemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning Points<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Tumour-induced osteomalacia is a difficult diagnosis as the tumour is often small and slow growing. Imaging may fail to identify a tumour, and treatment therefore consists of calcitriol and phosphate replacement.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Tumour-induced osteomalacia should be suspected in the adult presenting with new-onset hypophosphataemia, elevated FGF-23 levels and isolated renal phosphate wasting.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Serum phosphate is not part of the routine chemistry panels. Routinely checking phosphate levels prior to initiating antiresorptive therapy is warranted.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>DXA cannot distinguish low bone mineral density due to osteoporosis from osteomalacia. Antiresorptive therapy should be avoided in osteomalacia due to the risk of clinical and radiographic deterioration.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/edm-22-0300","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T10:55:52Z","timestamp":1670496952000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":3,"title":["Treating \u2018osteoporosis\u2019: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia"],"prefix":"10.1530","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-4193","authenticated-orcid":true,"given":"Mike","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Concord Repatriation General Hospital, Concord NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirtan","family":"Ganda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Concord Repatriation General Hospital, Concord NSW, Australia"},{"name":"The University of Sydney Concord Clinical School, Concord NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","article-title":"Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men","year":"2010","unstructured":"The Royal Australian College of General Practitioners. Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men [cited 2022 Sep 5]. Royal Australian College of General Practitioners2010. Available at: https:\/\/www.racgp.org.au\/download\/documents\/Guidelines\/Musculoskeletal\/racgp_osteo_guideline.pdf."},{"key":"bib2","series-title":"Bone","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","unstructured":"Brandi MLClunie GPRHouillier Pde Beur SMMinisola SOheim RSeefried L. Challenges in the management of tumor-induced osteomalacia (TIO). Bone2021152 116064 (https:\/\/doi.org\/10.1016\/j.bone.2021.116064)"},{"key":"bib3","series-title":"Calcified Tissue International","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano","year":"2021","unstructured":"Florenzano PHartley IRJimenez MRoszko KGafni RICollins MT. Tumor-induced osteomalacia. Calcified Tissue International2021108128\u2013142 (https:\/\/doi.org\/10.1007\/s00223-020-00691-6)10.1007\/s00223-020-00691-6"},{"key":"bib4","series-title":"Nuclear Medicine Communications","article-title":"Performance of 68Ga-DOTA-SST PET\/CT, Octreoscan SPECT\/CT and 18F-FDG PET\/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis","volume":"41","author":"Jiang","year":"2020","unstructured":"Jiang YHou GCheng W. Performance of 68Ga-DOTA-SST PET\/CT, Octreoscan SPECT\/CT and 18F-FDG PET\/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis. Nuclear Medicine Communications202041 370\u2013376 (https:\/\/doi.org\/10.1097\/MNM.0000000000001163)"},{"key":"bib5","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","unstructured":"Chong WHMolinolo AAChen CCCollins MT. Tumor-induced osteomalacia. Endocrine-Related Cancer201118R53\u2013R77 (https:\/\/doi.org\/10.1530\/ERC-11-0006)10.1530\/ERC-11-0006"},{"key":"bib6","series-title":"Journal of the Endocrine Society","article-title":"Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience","volume":"5","author":"Dahir","year":"2021","unstructured":"Dahir KZanchetta MBStanciu IRobinson CLee JYDhaliwal RCharles JCivitelli RRoberts MSKrolczyk SDiagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. Journal of the Endocrine Society20215 bvab099 (https:\/\/doi.org\/10.1210\/jendso\/bvab099)"},{"key":"bib7","series-title":"Journal of Bone and Mineral Research","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","unstructured":"Jan de Beur SMMiller PDWeber TJPeacock MInsogna KKumar RRauch FLuca DCimms TRoberts MSBurosumab for the treatment of tumor-induced osteomalacia. Journal of Bone and Mineral Research202136627\u2013635 (https:\/\/doi.org\/10.1002\/jbmr.4233)10.1002\/jbmr.4233"},{"key":"bib8","series-title":"Bone","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bone.2006.01.163","article-title":"Elevated serum FGF23 concentrations in plasma cell dyscrasias","volume":"39","author":"Stewart","year":"2006","unstructured":"Stewart IRoddie CGill AClarkson AMirams MCoyle LWard CClifton-Bligh PRobinson BGMason RSElevated serum FGF23 concentrations in plasma cell dyscrasias. Bone200639369\u2013376 (https:\/\/doi.org\/10.1016\/j.bone.2006.01.163)10.1016\/j.bone.2006.01.163"},{"key":"bib9","series-title":"JBMR Plus","article-title":"Bisphosphonate\u2010induced deterioration of osteomalacia in undiagnosed adult Fanconi syndrome","volume":"4","author":"Cundy","year":"2020","unstructured":"Cundy TQue LHassan IMHughes L. Bisphosphonate\u2010induced deterioration of osteomalacia in undiagnosed adult Fanconi syndrome. JBMR Plus20204 e10374 (https:\/\/doi.org\/10.1002\/jbm4.10374)"},{"key":"bib10","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1210\/jc.2004-0406","article-title":"Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia","volume":"89","author":"Takeuchi","year":"2004","unstructured":"Takeuchi YSuzuki HOgura SImai RYamazaki YYamashita TMiyamoto YOkazaki HNakamura KNakahara KVenous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism2004893979\u20133982 (https:\/\/doi.org\/10.1210\/jc.2004-0406)10.1210\/jc.2004-0406"},{"key":"bib11","series-title":"Yonsei Medical Journal","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3349\/ymj.2017.58.5.981","article-title":"Localization of oncogenic osteomalacia by systemic venous sampling of fibroblast growth factor 23","volume":"58","author":"Lee","year":"2017","unstructured":"Lee JYPark HSHan SLim JKHong NPark SIRhee Y. Localization of oncogenic osteomalacia by systemic venous sampling of fibroblast growth factor 23. Yonsei Medical Journal201758981\u2013987 (https:\/\/doi.org\/10.3349\/ymj.2017.58.5.981)10.3349\/ymj.2017.58.5.981"},{"key":"bib12","series-title":"Endocrine Practice","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4158\/EP.ep.14.3.362","article-title":"Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia","volume":"14","author":"Westerberg","year":"2008","unstructured":"Westerberg PAOlauson HToss GWikstr\u00f6m BMorales OLinde TJonsson KLjunggren OLarsson TE. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia. Endocrine Practice200814362\u2013367 (https:\/\/doi.org\/10.4158\/EP.14.3.362)10.4158\/EP.ep.14.3.362"},{"key":"bib13","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1530\/EJE-07-0779","article-title":"Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling","volume":"158","author":"Van Boekel","year":"2008","unstructured":"Van Boekel GRuinemans-Koerts JJoosten FDijkhuizen Pvan Sorge Ade Boer H. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. European Journal of Endocrinology2008158431\u2013437 (https:\/\/doi.org\/10.1530\/EJE-07-0779)10.1530\/EJE-07-0779"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2022\/1\/EDM22-0300.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2022\/1\/EDM22-0300.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2022\/1\/EDM22-0300.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:47:59Z","timestamp":1784555279000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.1530\/edm-22-0300","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}